116 related articles for article (PubMed ID: 28434350)
1. Antibody therapy for transthyretin-related hereditary amyloid polyneuropathy: another therapeutic option.
Ando Y; Ueda M
Amyloid; 2017 Mar; 24(sup1):113-114. PubMed ID: 28434350
[No Abstract] [Full Text] [Related]
2. Diflunisal compassive use in transthyretin hereditary amyloid polyneuropathy: report of a first Spanish experience.
Azorín SE; Cabib CE; Campistol JM
Amyloid; 2017 Mar; 24(sup1):105-106. PubMed ID: 28434315
[No Abstract] [Full Text] [Related]
3. Novel Antibody for the Treatment of Transthyretin Amyloidosis.
Hosoi A; Su Y; Torikai M; Jono H; Ishikawa D; Soejima K; Higuchi H; Guo J; Ueda M; Suenaga G; Motokawa H; Ikeda T; Senju S; Nakashima T; Ando Y
J Biol Chem; 2016 Nov; 291(48):25096-25105. PubMed ID: 27758856
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of amyloid neuropathy.
Kapoor M; Rossor AM; Jaunmuktane Z; Lunn MPT; Reilly MM
Pract Neurol; 2019 Jun; 19(3):250-258. PubMed ID: 30598431
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
Buxbaum JN
Amyloid; 2019 Jun; 26(2):55-65. PubMed ID: 30907141
[TBL] [Abstract][Full Text] [Related]
6. Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review.
Schmidt H; Cruz MW; Botteman MF; Carter JA; Chopra A; Stewart M; Hopps M; Fallet S; Amass L
Amyloid; 2017 Mar; 24(sup1):111-112. PubMed ID: 28434339
[No Abstract] [Full Text] [Related]
7. Tafamidis.
Said G; Grippon S; Kirkpatrick P
Nat Rev Drug Discov; 2012 Mar; 11(3):185-6. PubMed ID: 22378262
[TBL] [Abstract][Full Text] [Related]
8. Epidemiological and clinical characteristics of persons with transthyretin hereditary amyloid polyneuropathy: a global synthesis of 532 cases.
Cruz MW; Schmidt H; Botteman MF; Carter JA; Chopra AS; Stewart M; Hopps M; Fallet S; Amass L
Amyloid; 2017 Mar; 24(sup1):109-110. PubMed ID: 28434345
[No Abstract] [Full Text] [Related]
9. Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine.
Obayashi K; Tasaki M; Jono H; Ueda M; Shinriki S; Misumi Y; Yamashita T; Oshima T; Nakamura T; Ikemizu S; Anan I; Suhr O; Ando Y
Clin Chim Acta; 2013 Apr; 419():127-31. PubMed ID: 23462670
[TBL] [Abstract][Full Text] [Related]
10. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
Merkies IS
Neurology; 2013 Apr; 80(15):1444-5. PubMed ID: 23569001
[No Abstract] [Full Text] [Related]
11. Discovering transthyretin amyloid fibril inhibitors by limited screening.
Baures PW; Peterson SA; Kelly JW
Bioorg Med Chem; 1998 Aug; 6(8):1389-401. PubMed ID: 9784876
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the effects of transthyretin peptide inhibitors in Drosophila models of neuropathic ATTR.
Saelices L; Pokrzywa M; Pawelek K; Eisenberg DS
Neurobiol Dis; 2018 Dec; 120():118-125. PubMed ID: 30213731
[TBL] [Abstract][Full Text] [Related]
13. Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule.
Rocha A; Silva A; Cardoso M; Beirão I; Alves C; Teles P; Coelho T; Lobato L
Amyloid; 2017 Mar; 24(sup1):81-82. PubMed ID: 28434370
[No Abstract] [Full Text] [Related]
14. [Transthyretin familial amyloid polyneuropathy - three Hungarian cases with rare mutations (His88Arg and Phe33Leu)].
Csillik A; Pozsonyi Z; Soós K; Balogh I; Bodó I; Arányi Z
Ideggyogy Sz; 2016 Jul; 69(7-8):245-253. PubMed ID: 29465889
[TBL] [Abstract][Full Text] [Related]
15. Curcumin could reduce the monomer of TTR with Tyr114Cys mutation via autophagy in cell model of familial amyloid polyneuropathy.
Li H; Zhang Y; Cao L; Xiong R; Zhang B; Wu L; Zhao Z; Chen SD
Drug Des Devel Ther; 2014; 8():2121-8. PubMed ID: 25382970
[TBL] [Abstract][Full Text] [Related]
16. Antibody therapy for familial amyloidotic polyneuropathy.
Su Y; Jono H; Torikai M; Hosoi A; Soejima K; Guo J; Tasaki M; Misumi Y; Ueda M; Shinriki S; Shono M; Obayashi K; Nakashima T; Sugawara K; Ando Y
Amyloid; 2012 Jun; 19 Suppl 1():45-6. PubMed ID: 22506915
[TBL] [Abstract][Full Text] [Related]
17. Rational design of potent human transthyretin amyloid disease inhibitors.
Klabunde T; Petrassi HM; Oza VB; Raman P; Kelly JW; Sacchettini JC
Nat Struct Biol; 2000 Apr; 7(4):312-21. PubMed ID: 10742177
[TBL] [Abstract][Full Text] [Related]
18. Wild-type transthyretin significantly contributes to the formation of amyloid fibrils in familial amyloid polyneuropathy patients with amyloidogenic transthyretin Val30Met.
Tsuchiya-Suzuki A; Yazaki M; Kametani F; Sekijima Y; Ikeda S
Hum Pathol; 2011 Feb; 42(2):236-43. PubMed ID: 21056899
[TBL] [Abstract][Full Text] [Related]
19. [Transthyretin-related hereditary amyloidosis].
Vionnet J; Pascual M; Kuntzer T; Yerly P; Moradpour D
Rev Med Suisse; 2016 Aug; 12(528):1434-1440. PubMed ID: 28675284
[TBL] [Abstract][Full Text] [Related]
20. Toward the discovery of functional transthyretin amyloid inhibitors: application of virtual screening methods.
Simões CJ; Mukherjee T; Brito RM; Jackson RM
J Chem Inf Model; 2010 Oct; 50(10):1806-20. PubMed ID: 20883031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
